AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bromocriptine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 403 | 25614-03-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
| 5 | mg | P |
| 40 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.19 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 28 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK2,PDK4,PRKDC,TEK | 17 | |||
| kinase-selectivity-class | PDK1 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 28, 1978 | FDA | US PHARMS HOLDINGS I |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Visual pathway disorder | 61.33 | 24.50 | 8 | 2654 | 39 | 90625746 |
| Exposure during pregnancy | 57.63 | 24.50 | 51 | 2611 | 238359 | 90387426 |
| Blood prolactin increased | 54.40 | 24.50 | 14 | 2648 | 3623 | 90622162 |
| Maternal exposure during pregnancy | 53.44 | 24.50 | 59 | 2603 | 360004 | 90265781 |
| Neuroleptic malignant syndrome | 49.17 | 24.50 | 18 | 2644 | 15078 | 90610707 |
| Mediastinal fibrosis | 43.78 | 24.50 | 6 | 2656 | 45 | 90625740 |
| Pituitary tumour | 43.23 | 24.50 | 9 | 2653 | 920 | 90624865 |
| Hyperprolactinaemia | 40.03 | 24.50 | 12 | 2650 | 5421 | 90620364 |
| Body height increased | 32.90 | 24.50 | 5 | 2657 | 82 | 90625703 |
| Pituitary tumour removal | 32.73 | 24.50 | 4 | 2658 | 10 | 90625775 |
| Catatonia | 30.49 | 24.50 | 10 | 2652 | 6046 | 90619739 |
| Muscle neoplasm | 28.44 | 24.50 | 4 | 2658 | 37 | 90625748 |
| Gallbladder neoplasm | 28.25 | 24.50 | 4 | 2658 | 39 | 90625746 |
| Hemianopia heteronymous | 27.56 | 24.50 | 4 | 2658 | 47 | 90625738 |
| Lymphatic system neoplasm | 27.56 | 24.50 | 4 | 2658 | 47 | 90625738 |
| Psychomotor hyperactivity | 26.52 | 24.50 | 11 | 2651 | 12802 | 90612983 |
| Blood prolactin decreased | 26.19 | 24.50 | 4 | 2658 | 68 | 90625717 |
| Insulin-like growth factor increased | 26.11 | 24.50 | 6 | 2656 | 968 | 90624817 |
| Pituitary haemorrhage | 25.16 | 24.50 | 4 | 2658 | 89 | 90625696 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 153.62 | 25.97 | 49 | 1557 | 21423 | 42598306 |
| Gambling disorder | 71.78 | 25.97 | 16 | 1590 | 1760 | 42617969 |
| Serotonin syndrome | 70.64 | 25.97 | 29 | 1577 | 25816 | 42593913 |
| Stress cardiomyopathy | 59.61 | 25.97 | 15 | 1591 | 2770 | 42616959 |
| Muscle rigidity | 56.26 | 25.97 | 20 | 1586 | 12039 | 42607690 |
| Neonatal respiratory depression | 41.01 | 25.97 | 8 | 1598 | 458 | 42619271 |
| Hypersexuality | 35.59 | 25.97 | 9 | 1597 | 1693 | 42618036 |
| Borderline personality disorder | 35.37 | 25.97 | 7 | 1599 | 432 | 42619297 |
| Premature baby | 31.49 | 25.97 | 16 | 1590 | 23137 | 42596592 |
| Impulse-control disorder | 31.31 | 25.97 | 8 | 1598 | 1567 | 42618162 |
| Blood prolactin increased | 28.31 | 25.97 | 8 | 1598 | 2290 | 42617439 |
| Hyperthermia | 27.30 | 25.97 | 12 | 1594 | 12562 | 42607167 |
| Drug ineffective | 26.84 | 25.97 | 67 | 1539 | 630130 | 41989599 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 196.37 | 20.91 | 65 | 3822 | 33994 | 110551418 |
| Muscle rigidity | 64.03 | 20.91 | 26 | 3861 | 24005 | 110561407 |
| Blood prolactin increased | 62.19 | 20.91 | 17 | 3870 | 4625 | 110580787 |
| Maternal exposure during pregnancy | 55.88 | 20.91 | 56 | 3831 | 254827 | 110330585 |
| Gambling disorder | 53.77 | 20.91 | 13 | 3874 | 2178 | 110583234 |
| Visual pathway disorder | 52.95 | 20.91 | 8 | 3879 | 104 | 110585308 |
| Exposure during pregnancy | 52.63 | 20.91 | 45 | 3842 | 167379 | 110418033 |
| Serotonin syndrome | 49.60 | 20.91 | 29 | 3858 | 59124 | 110526288 |
| Stress cardiomyopathy | 48.71 | 20.91 | 19 | 3868 | 15787 | 110569625 |
| Mediastinal fibrosis | 42.70 | 20.91 | 6 | 3881 | 45 | 110585367 |
| Hyperprolactinaemia | 39.64 | 20.91 | 13 | 3874 | 6562 | 110578850 |
| Pituitary haemorrhage | 37.92 | 20.91 | 7 | 3880 | 319 | 110585093 |
| Hyperthermia | 33.79 | 20.91 | 16 | 3871 | 21256 | 110564156 |
| Pituitary tumour | 33.67 | 20.91 | 8 | 3879 | 1245 | 110584167 |
| Drug ineffective | 33.61 | 20.91 | 123 | 3764 | 1520417 | 109064995 |
| Chiasma syndrome | 31.74 | 20.91 | 4 | 3883 | 11 | 110585401 |
| Pituitary tumour removal | 30.21 | 20.91 | 4 | 3883 | 18 | 110585394 |
| Impulse-control disorder | 29.22 | 20.91 | 8 | 3879 | 2186 | 110583226 |
| Autonomic nervous system imbalance | 29.18 | 20.91 | 10 | 3877 | 5770 | 110579642 |
| Psychomotor hyperactivity | 28.42 | 20.91 | 14 | 3873 | 20263 | 110565149 |
| Blood creatine phosphokinase increased | 27.87 | 20.91 | 22 | 3865 | 73055 | 110512357 |
| Abnormal behaviour | 27.19 | 20.91 | 17 | 3870 | 39022 | 110546390 |
| Muscle neoplasm | 26.07 | 20.91 | 4 | 3883 | 58 | 110585354 |
| Catatonia | 25.95 | 20.91 | 11 | 3876 | 11289 | 110574123 |
| Blood prolactin decreased | 25.69 | 20.91 | 5 | 3882 | 303 | 110585109 |
| Hypersexuality | 25.49 | 20.91 | 7 | 3880 | 1933 | 110583479 |
| Lymphatic system neoplasm | 25.10 | 20.91 | 4 | 3883 | 75 | 110585337 |
| Gallbladder neoplasm | 24.62 | 20.91 | 4 | 3883 | 85 | 110585327 |
| Insulin-like growth factor increased | 24.33 | 20.91 | 7 | 3880 | 2289 | 110583123 |
| Hemianopia heteronymous | 24.28 | 20.91 | 4 | 3883 | 93 | 110585319 |
| Adenoma benign | 23.26 | 20.91 | 6 | 3881 | 1307 | 110584105 |
| Drug ineffective for unapproved indication | 23.23 | 20.91 | 23 | 3864 | 102815 | 110482597 |
| Pituitary tumour benign | 22.84 | 20.91 | 7 | 3880 | 2840 | 110582572 |
| Foetal death | 22.26 | 20.91 | 11 | 3876 | 16034 | 110569378 |
| Stupor | 22.20 | 20.91 | 9 | 3878 | 8256 | 110577156 |
| Body height increased | 22.18 | 20.91 | 4 | 3883 | 160 | 110585252 |
| Malignant catatonia | 21.56 | 20.91 | 5 | 3882 | 701 | 110584711 |
| Drug resistance | 21.55 | 20.91 | 17 | 3870 | 56357 | 110529055 |
| Persecutory delusion | 20.94 | 20.91 | 8 | 3879 | 6283 | 110579129 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02CB01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Prolactine inhibitors |
| ATC | N04BC01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopamine agonists |
| FDA CS | M0007652 | Ergolines |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:49020 | hormone antagonist |
| CHEBI has role | CHEBI:50779 | appetite enhancer |
| CHEBI has role | CHEBI:51065 | dopamine agonist |
| CHEBI has role | CHEBI:66956 | antidyskinesia agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018491 | Dopamine Agonists |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| FDA EPC | N0000175827 | Ergot Derivative |
Related Drugs by ATC class:
G02CB Prolactine inhibitors 5 drugs
N04BC Dopamine agonists 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postencephalitic parkinsonism | indication | 19972008 | DOID:14332 |
| Parkinson's disease | indication | 49049000 | DOID:14330 |
| Acromegaly | indication | 74107003 | DOID:2449 |
| Hyperprolactinemia | indication | 237662005 | DOID:12700 |
| Type 2 Diabetes Mellitus Treatment Adjunct | indication | ||
| Neuroleptic malignant syndrome | off-label use | 15244003 | DOID:14464 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Severe pre-eclampsia | contraindication | 46764007 | |
| Pregnancy-induced hypertension | contraindication | 48194001 | |
| Eclampsia in pregnancy | contraindication | 198992004 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Psychiatric Disturbance | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.98 | acidic |
| pKa2 | 12.93 | acidic |
| pKa3 | 5.98 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688155 | June 7, 2030 | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 8877708 | June 7, 2030 | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9352025 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9895422 | June 7, 2030 | ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 10688094 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11000522 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11000522 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11000522 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11000522 | April 30, 2032 | ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11666567 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 10, AND 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11666567 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 21, AND 22 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11666567 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 21 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 11666567 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 8431155 | April 30, 2032 | IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 8613947 | April 30, 2032 | IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9192576 | April 30, 2032 | IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9522117 | April 30, 2032 | ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9522117 | April 30, 2032 | IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9700555 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11 |
| EQ 0.8MG BASE | CYCLOSET | VEROSCIENCE | N020866 | May 5, 2009 | RX | TABLET | ORAL | 9993474 | April 30, 2032 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10 |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | AGONIST | Ki | 9.70 | WOMBAT-PK | CHEMBL | |||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.86 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | AGONIST | Ki | 6.20 | IUPHAR | ||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 8 | WOMBAT-PK | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 7.90 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 7 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.30 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.10 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 7.50 | IUPHAR | ||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.38 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.50 | WOMBAT-PK | |||||
| D(3) dopamine receptor | GPCR | AGONIST | Ki | 7.50 | WOMBAT-PK | ||||
| D(1B) dopamine receptor | GPCR | AGONIST | Ki | 6.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.50 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 8 | WOMBAT-PK | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.60 | WOMBAT-PK | |||||
| D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR | ||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 8.55 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 8.86 | PDSP | |||||
| Alpha-synuclein | Transporter | IC50 | 4.61 | CHEMBL | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 6.13 | PDSP | |||||
| Androgen receptor | Transcription factor | Ki | 5.82 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 8.71 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.33 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 8.16 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Kd | 8.40 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 8.25 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 8 | IUPHAR | ||||
| Vesicular glutamate transporter 3 | Transporter | IC50 | 4.66 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 7.50 | IUPHAR | ||||
| Adrenergic receptor alpha-2 | GPCR | IC50 | 6.29 | CHEMBL | |||||
| Dopamine receptor | GPCR | IC50 | 7.55 | CHEMBL | |||||
| Cerebral cortex alpha adrenergic receptor | GPCR | IC50 | 6.29 | CHEMBL | |||||
| Genome polyprotein | Polyprotein | EC50 | 4.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019639 | VUID |
| N0000147732 | NUI |
| D00780 | KEGG_DRUG |
| 22260-51-1 | SECONDARY_CAS_RN |
| 142426 | RXNORM |
| C0006230 | UMLSCUI |
| CHEBI:3181 | CHEBI |
| 08Y | PDB_CHEM_ID |
| CHEMBL493 | ChEMBL_ID |
| CHEMBL311816 | ChEMBL_ID |
| CHEMBL1200503 | ChEMBL_ID |
| D001971 | MESH_DESCRIPTOR_UI |
| DB01200 | DRUGBANK_ID |
| 35 | IUPHAR_LIGAND_ID |
| 3365 | INN_ID |
| 3A64E3G5ZO | UNII |
| 31101 | PUBCHEM_CID |
| 10007 | MMSL |
| 4300 | MMSL |
| d00178 | MMSL |
| 116656002 | SNOMEDCT_US |
| 387039007 | SNOMEDCT_US |
| 46293006 | SNOMEDCT_US |
| 4018752 | VANDF |
| 4019639 | VANDF |
| 002117 | NDDF |
| 002118 | NDDF |
| 3A64E3G5ZO | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bromocriptine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7096 | CAPSULE | 5 mg | ORAL | ANDA | 21 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0106 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5325 | TABLET | 2.50 mg | ORAL | ANDA | 18 sections |
| Parlodel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-201 | CAPSULE, GELATIN COATED | 5 mg | ORAL | NDA | 21 sections |
| Parlodel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-202 | TABLET | 2.50 mg | ORAL | NDA | 21 sections |
| Bromocriptine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5667 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Bromocriptine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-931 | TABLET | 2.50 mg | ORAL | NDA | 19 sections |
| BROMOCRIPTINE MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-158 | CAPSULE | 5 mg | ORAL | NDA | 14 sections |
| BROMOCRIPTINE MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-962 | TABLET | 2.50 mg | ORAL | NDA | 14 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65841-654 | CAPSULE | 5 mg | ORAL | ANDA | 1 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1305 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68382-110 | CAPSULE | 5 mg | ORAL | ANDA | 13 sections |
| Bromocriptine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4628 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
| Bromocriptine Mesylate | Human Prescription Drug Label | 1 | 70954-951 | CAPSULE | 5 mg | ORAL | NDA | 19 sections |
| Bromocriptine Mesylate | Human Prescription Drug Label | 1 | 70954-978 | TABLET | 2.50 mg | ORAL | NDA | 19 sections |
| CYCLOSET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73515-123 | TABLET | 0.80 mg | ORAL | NDA | 30 sections |